PXS-5505A is under clinical development by Pharmaxis and currently in Phase II for Post-Polycythemia Vera Myelofibrosis (PPV-MF). According to GlobalData, Phase II drugs for Post-Polycythemia Vera Myelofibrosis (PPV-MF) have a 58% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how PXS-5505A’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

PXS-5505A overview

PXS-5505A is under development for the treatment of myelofibrosis, kidney fibrosis, myelodysplastic syndrome, lung fibrosis, liver cancer, cholangiocarcinoma (CCA) pancreatic cancer, primary myelofibrosis, post polycythemia vera (PV) myelofibrosis and post-essential thrombocythemia (ET) myelofibrosis. It is administered by oral route in the form of capsule. The drug candidate acts by targeting lysyl oxidase (LOX), LOX1, LOX2, LOX3 and LOX4 and is developed based on amine oxidase platform technology. It was also under development for melanoma, malignant mesothelioma, glioblastoma multiforme (GBM), liver fibrosis and fibrosis and head and neck cancer and metastatic hepatocellular carcinoma.

Pharmaxis overview

Pharmaxis is a clinical stage drug development company. It develops drugs for inflammatory, fibrotic and selected cancer indications diseases. The company product pipeline comprises of PXS-5505, PXS-5382, PXS-6302, PXS-4728, PXS-4699 and PXS-5370. Pharmaxis therapeutic areas includes myelofibrosis, liver and pancreatic cancer, pulmonary fibrosis, anti-fibrotic, IPF, CKD and NASH, anti-scarring, burns, established scars, isolated rapid eye movement sleep behaviour disorder (IRBD), parkinson’s disease, anti-inflammatory and multiple indications. The company provide orbital dry powder inhaler. It sells its products under the brands Bronchitol and Aridol. Pharmaxis is headquartered in Sydney, Frenchs Forest, Australia.

For a complete picture of PXS-5505A’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 2 September 2023

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.